Genmab — April 2020
-
-
Ocrevus is the only approved treatment for primary progressive MS with off-label use also reported in secondary progressive disease. In the short term, KOLs anticipate Novartis’ ofatumumab posing the most significant competitive threat to Roche’s drug, citing its subcutaneous formulation and faster B-cell repletion as significant advantages. Approval of ofatumumab is expected later this year.
-
on that SC ; recent Novartis comment: said that roughly 40% of MS patients are treated at community centres in the US and these centres like to keep the patients in-house. Therefore they see SC as a major advantage compared to an IV formulated version with clinic/hospital visit.
-
God morgen.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind